CLIENT CODE.



## PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

: 13/Jul/2024 01:56PM

20 - 40

1-6

**NAME** : Mrs. NIRMAL KAUR

**AGE/ GENDER** : 63 YRS/FEMALE **PATIENT ID** : 1547457

**COLLECTED BY** REG. NO./LAB NO. : 122407130003

REFERRED BY **REGISTRATION DATE** : 13/Jul/2024 08:39 AM BARCODE NO. : 12503570 **COLLECTION DATE** : 13/Jul/2024 08:56AM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

Test Name Value Unit **Biological Reference interval** 

### **HAEMATOLOGY**

REPORTING DATE

### **COMPLETE BLOOD COUNT (CBC)**

|--|

by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY

HAEMOGLOBIN (HB)	12	gm/dL	12.0 - 16.0
by CALORIMETRIC  RED BLOOD CELL (RBC) COUNT  by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	4.5	Millions/cmm	3.50 - 5.00
PACKED CELL VOLUME (PCV) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	35.7 <sup>L</sup>	%	37.0 - 50.0
MEAN CORPUSCULAR VOLUME (MCV)  by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	79.4 <sup>L</sup> PKR	fL	80.0 - 100.0
MEAN CORPUSCULAR HAEMOGLOBIN (MCH)  by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	26.7 <sup>L</sup>	pg	27.0 - 34.0
MEAN CORPUSCULAR HEMOGLOBIN CONC. (MCHC) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	33.7	g/dL	32.0 - 36.0
RED CELL DISTRIBUTION WIDTH (RDW-CV)  by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	13.4	%	11.00 - 16.00
RED CELL DISTRIBUTION WIDTH (RDW-SD)  by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	40.7	fL	35.0 - 56.0
MENTZERS INDEX by CALCULATED	17.64	RATIO	BETA THALASSEMIA TRAIT: < 13.0 IRON DEFICIENCY ANEMIA: >13.0
GREEN & KING INDEX by CALCULATED	23.67	RATIO	BETA THALASSEMIA TRAIT: < = 65.0 IRON DEFICIENCY ANEMIA: > 65.0
WHITE BLOOD CELLS (WBCS)			INON DEFICIENCE ANEIVIA. > 05.0
TOTAL LEUCOCYTE COUNT (TLC) by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY DIFFERENTIAL LEUCOCYTE COUNT (DLC)	5460	/cmm	4000 - 11000
NEUTROPHILS by flow cytometry by SF cube & microscopy	45 <sup>L</sup>	%	50 - 70



LYMPHOCYTES

**EOSINOPHILS** 

CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



47<sup>H</sup>

2





### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

NAME : Mrs. NIRMAL KAUR

**AGE/ GENDER** : 63 YRS/FEMALE **PATIENT ID** : 1547457

**COLLECTED BY** REG. NO./LAB NO. : 122407130003

REFERRED BY **REGISTRATION DATE** : 13/Jul/2024 08:39 AM BARCODE NO. : 12503570 **COLLECTION DATE** : 13/Jul/2024 08:56AM

CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 13/Jul/2024 01:56PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	Biological Reference interval
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY			
MONOCYTES	6	%	2 - 12
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY			
BASOPHILS	0	%	0 - 1
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY  ABSOLUTE LEUKOCYTES (WBC) COUNT			
ABSOLUTE NEUTROPHIL COUNT	2457	/cmm	2000 - 7500
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY ABSOLUTE LYMPHOCYTE COUNT		lanana	000 4000
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	2566 <sup>L</sup>	/cmm	800 - 4900
ABSOLUTE EOSINOPHIL COUNT	109	/cmm	40 - 440
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	PKR	7 (111111	10 110
ABSOLUTE MONOCYTE COUNT	328	/cmm	80 - 880
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY			
ABSOLUTE BASOPHIL COUNT	0	/cmm	0 - 110
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	De		
PLATELETS AND OTHER PLATELET PREDICTIVE MARKE	<u>RS.</u>		
PLATELET COUNT (PLT)	184000	/cmm	150000 - 450000
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE		04	0.10007
PLATELETCRIT (PCT) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	0.2	%	0.10 - 0.36
MEAN PLATELET VOLUME (MPV)	11	fL	6.50 - 12.0
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE		IL.	0.30 - 12.0
PLATELET LARGE CELL COUNT (P-LCC)	64000	/cmm	30000 - 90000
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE			
PLATELET LARGE CELL RATIO (P-LCR)	34.8	%	11.0 - 45.0
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	47.4	04	45.0.47.0
PLATELET DISTRIBUTION WIDTH (PDW) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	16.4	%	15.0 - 17.0
NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD			
TIOTE. TEST CONDUCTED ON EDITY WHOLE BEOOD			



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS, MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST





### PKR JAIN HEALTHCARE INSTITUTE

NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

REPORTING DATE

: 13/Jul/2024 04:22PM

**NAME** : Mrs. NIRMAL KAUR

AGE/ GENDER : 63 YRS/FEMALE **PATIENT ID** : 1547457

**COLLECTED BY** : 122407130003 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 13/Jul/2024 08:39 AM BARCODE NO. : 12503570 **COLLECTION DATE** : 13/Jul/2024 08:56AM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

Value Unit **Biological Reference interval** Test Name

### **GLYCOSYLATED HAEMOGLOBIN (HBA1C)**

GLYCOSYLATED HAEMOGLOBIN (HbA1c): 9H 4.0 - 6.4

WHOLE BLOOD by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

mg/dL ESTIMATED AVERAGE PLASMA GLUCOSE 211.6H 60.00 - 140.00

by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY) **INTERPRETATION:** 

AS PER AMERICAN DIABETES ASSOCIATION (ADA):			
REFERENCE GROUP	GLYCOSYLATED HEMOGLOGIB (HBAIC) in %		
Non diabetic Adults >= 18 years	<5.7		
At Risk (Prediabetes)	5.7 <b>-</b> 6.4		
Diagnosing Diabetes	>= 6.5		
	Age > 19 Yea	ars	
Therapeutic goals for glycemic control	Goals of Therapy:	< 7.0	
	Actions Suggested:	>8.0	
	Age < 19 Years		
	Goal of therapy:	<7.5	

#### COMMENTS:

CLIENT CODE.

- 1. Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients.
- 2. Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.
- 3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be 4.High

HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications

5. Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7. Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





CLIENT CODE.



## PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

REPORTING DATE

: 13/Jul/2024 04:22PM

**NAME** : Mrs. NIRMAL KAUR

**AGE/ GENDER** : 63 YRS/FEMALE **PATIENT ID** : 1547457

**COLLECTED BY** REG. NO./LAB NO. : 122407130003

REFERRED BY **REGISTRATION DATE** : 13/Jul/2024 08:39 AM BARCODE NO. : 12503570 **COLLECTION DATE** : 13/Jul/2024 08:56AM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA


: P.K.R JAIN HEALTHCARE INSTITUTE

Test Name Value Unit **Biological Reference interval** 

#### LIFOTRONIC Graph Report

Name :	Case:	Patient Type :	Test Date: 13/07/2024 16:09:10
Age:	Department:	Sample Type: Whole Blood EDTA	Sample ld: 12503570
Gender:			Total Area: 10304

Peak Name	Retention Time(s)	Absorbance	Area	Result (Area %)
HbA0	69	2632	8956	84.9
HbA1c	36	99	952	9.0
La1c	28	17	164	1.5
HbF	21	13	11	0.1
Hba1b	13	49	127	1.2
Hba1a	11	31	94	0.9





CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



CLIENT CODE.



## PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

REPORTING DATE

: 13/Jul/2024 03:44PM

60.0

**NAME** : Mrs. NIRMAL KAUR

AGE/ GENDER : 63 YRS/FEMALE **PATIENT ID** : 1547457

**COLLECTED BY** REG. NO./LAB NO. : 122407130003

REFERRED BY **REGISTRATION DATE** : 13/Jul/2024 08:39 AM BARCODE NO. **COLLECTION DATE** : 13/Jul/2024 08:56AM : 12503570

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

Value Unit Test Name **Biological Reference interval** 

### CLINICAL CHEMISTRY/BIOCHEMISTRY

LIPID PROFILE: BASIC

CHOLESTEROL TOTAL: SERUM mg/dL **OPTIMAL:** < 200.0 220.08<sup>H</sup>

by CHOLESTEROL OXIDASE PAP **BORDERLINE HIGH: 200.0 - 239.0** HIGH CHOLESTEROL: > OR = 240.0

TRIGLYCERIDES: SERUM 373.93H mg/dL **OPTIMAL:** < 150.0

by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC) **BORDERLINE HIGH: 150.0 - 199.0** HIGH: 200.0 - 499.0

VERY HIGH: > OR = 500.0

HDL CHOLESTEROL (DIRECT): SERUM LOW HDL: < 30.0 46.87 mg/dL by SELECTIVE INHIBITION BORDERLINE HIGH HDL: 30.0 -

 $HIGH\ HDL: > OR = 60.0$ LDL CHOLESTEROL: SERUM 98.42 OPTIMAL: < 100.0 mg/dL

by CALCULATED, SPECTROPHOTOMETRY ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0

HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0

NON HDL CHOLESTEROL: SERUM **OPTIMAL: < 130.0** 173.21H mg/dL

by CALCULATED, SPECTROPHOTOMETRY ABOVE OPTIMAL: 130.0 - 159.0 **BORDERLINE HIGH: 160.0 - 189.0** 

HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0

VLDL CHOLESTEROL: SERUM mg/dL 0.00 - 45.0074.79<sup>H</sup> by CALCULATED, SPECTROPHOTOMETRY

**TOTAL LIPIDS: SERUM** 350.00 - 700.00 814.09<sup>H</sup> mg/dL

by CALCULATED, SPECTROPHOTOMETRY

CHOLESTEROL/HDL RATIO: SERUM 4.7<sup>H</sup> LOW RISK: 3.30 - 4.40 **RATIO** by CALCULATED, SPECTROPHOTOMETRY **AVERAGE RISK: 4.50 - 7.0** 

**MODERATE RISK: 7.10 - 11.0** 

**HIGH RISK: > 11.0** 

LDL/HDL RATIO: SERUM **RATIO** LOW RISK: 0.50 - 3.0 2.1



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







### A PIONEER DIAGNOSTIC CENTRE

REPORTING DATE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

**NAME** : Mrs. NIRMAL KAUR

AGE/ GENDER : 63 YRS/FEMALE **PATIENT ID** : 1547457

**COLLECTED BY** REG. NO./LAB NO. : 122407130003

REFERRED BY **REGISTRATION DATE** : 13/Jul/2024 08:39 AM BARCODE NO. **COLLECTION DATE** : 13/Jul/2024 08:56AM : 12503570

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

Value Unit **Biological Reference interval Test Name** 

by CALCULATED, SPECTROPHOTOMETRY MODERATE RISK: 3.10 - 6.0

HIGH RISK: > 6.0

: 13/Jul/2024 03:44PM

TRIGLYCERIDES/HDL RATIO: SERUM **RATIO** 3.00 - 5.00 $7.98^{H}$ 

by CALCULATED. SPECTROPHOTOMETRY INTERPRETATION:

CLIENT CODE.

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co-primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

**NAME** : Mrs. NIRMAL KAUR

**AGE/ GENDER** : 63 YRS/FEMALE **PATIENT ID** : 1547457

**COLLECTED BY** REG. NO./LAB NO. : 122407130003

REFERRED BY **REGISTRATION DATE** : 13/Jul/2024 08:39 AM BARCODE NO. : 12503570 **COLLECTION DATE** : 13/Jul/2024 08:56AM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 13/Jul/2024 04:26PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval** 

### **KIDNEY FUNCTION TEST (BASIC)**

UREA: SERUM by urease - glutamate dehydrogenase (gldh)	50.36 <sup>H</sup>	mg/dL	10.00 - 50.00
CREATININE: SERUM by ENZYMATIC, SPECTROPHOTOMETERY	1.52 <sup>H</sup>	mg/dL	0.40 - 1.20
BLOOD UREA NITROGEN (BUN): SERUM by CALCULATED, SPECTROPHOTOMETERY	23.53 <sup>H</sup>	mg/dL	7.0 - 25.0
BLOOD UREA NITROGEN (BUN)/CREATININE RATIO: SERUM	15.48	RATIO	10.0 - 20.0
by CALCULATED, SPECTROPHOTOMETERY			
UREA/CREATININE RATIO: SERUM by CALCULATED, SPECTROPHOTOMETERY	33.13	RATIO	
URIC ACID: SERUM by URICASE - OXIDASE PEROXIDASE	7.27 <sup>H</sup>	mg/dL	2.50 - 6.80
NOTE 2	RESULT RECHECKED TWICE		
ADVICE	KINDLY CORRELATE CLINICALLY		



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

**NAME** : Mrs. NIRMAL KAUR

AGE/ GENDER : 63 YRS/FEMALE **PATIENT ID** : 1547457

**COLLECTED BY** REG. NO./LAB NO. : 122407130003

REFERRED BY **REGISTRATION DATE** : 13/Jul/2024 08:39 AM BARCODE NO. **COLLECTION DATE** : 13/Jul/2024 08:56AM : 12503570 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 13/Jul/2024 04:26PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval** 

**INTERPRETATION:** 

Normal range for a healthy person on normal diet: 12 - 20

To Differentiate between pre- and postrenal azotemia. INCREASED RATIO (>20:1) WITH NORMAL CREATININE:

1. Prerenal azotemia (BUN rises without increase in creatinine) e.g. heart failure, salt depletion, dehydration, blood loss) due to decreased glomerular filtration rate.

Ž.Catabolic states with increased tissue breakdown.

3.GI hemorrhage.

4. High protein intake.

5. Impaired renal function plus.

6. Excess protein intake or production or tissue breakdown (e.g. infection, GI bleeding, thyrotoxicosis, Cushings syndrome, high protein diet, burns, surgery, cachexia, high fever)

7. Urine reabsorption (e.g. ureterocolostomy)
8. Reduced muscle mass (subnormal creatinine production)
9. Certain drugs (e.g. tetracycline, glucocorticoids)
INCREASED RATIO (>20:1) WITH ELEVATED CREATININE LEVELS:

1. Postrenal azotemia (BUN rises disproportionately more than creatinine) (e.g. obstructive uropathy).

2. Prerenal azotemia superimposed on renal disease.

#### DECREASED RATIO (<10:1) WITH DECREASED BUN:

1.Acute tubular necrosis.

2.Low protein diet and starvation.

3. Severe liver disease.

4. Other causes of decreased urea synthesis.

5. Repeated dialysis (urea rather than creatinine diffuses out of extracellular fluid).

6.Inherited hyperammonemias (urea is virtually absent in blood)

7.SIADH (syndrome of inappropiate antidiuretic harmone) due to tubular secretion of urea.

8. Pregnancy

DECREASED RATIO (<10:1) WITH INCREASED CREATININE:

- 1. Phenacimide therapy (accelerates conversion of creatine to creatinine).
- 2. Rhabdomyolysis (releases muscle creatinine).
- 3. Muscular patients who develop renal failure

#### **INAPPROPIATE RATIO**

1. Diabetic ketoacidosis (acetoacetate causes false increase in creatinine with certain methodologies, resulting in normal ratio when dehydration should produce an increased BUN/creatinine ratio).

2. Cephalosporin therapy (interferes with creatinine measurement).

\*\*\* End Of Report \*\*\*

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

